Background: Patients with psoriasis experience decreased health-related quality of life due to physical and psychological burdens.
Objective: To assess the effect of a highly effective psoriasis treatment (secukinumab) on domains of the 3-level EuroQol 5 Dimensions questionnaire (EQ-5D-3L) in patients with moderate-to-severe psoriasis who reported problems at baseline.
Methods: This pooled analysis of four phase 3 clinical trials (ERASURE [NCT01365455], FIXTURE [NCT01358578], FEATURE [NCT01555125], and JUNCTURE [NCT01636687]) included patients with moderate-to-severe psoriasis randomized to receive placebo or secukinumab 300 mg and who reported problems in the EQ-5D-3L domains of mobility, self-care, usual activities, pain/discomfort, or anxiety/depression at baseline. Percentage of patients reporting problems in each domain were compared at Weeks 4, 8, and 12 between patients receiving secukinumab 300 mg and placebo.
Results: At baseline, 570 patients receiving secukinumab 300 mg and 579 receiving placebo reported ≥1 problem in the EQ-5D-3L domains. Patients receiving secukinumab 300 mg reported improvements in all 5 domains at Weeks 4, 8, and 12 compared with placebo (all p < .0001).
Conclusion: These findings provide additional evidence of the quality-of-life impairment in patients with moderate-to-severe psoriasis and highlight the improvement across all EQ-5D-3L domains among patients treated with secukinumab.
Keywords: EQ-5D; Psoriasis; quality of life; secukinumab.